Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
or

Aeglea Biothera (AGLE)

Aeglea Biothera (AGLE)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
12.01 +0.97 (+8.79%) 11/27/23 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 12.01 unch (unch) -
Quote Overview for Mon, Nov 27th, 2023
Day Low
10.69
Day High
12.34
Open 10.87
Previous Close 11.04 11.04
Volume 43,300 43,300
Avg Vol 52,140 52,140
Stochastic %K 74.17% 74.17%
Weighted Alpha -15.70 -15.70
5-Day Change +1.76 (+17.17%) +1.76 (+17.17%)
52-Week Range 2.66 - 32.75 2.66 - 32.75
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 48,627
  • Shares Outstanding, K 4,049
  • Annual Sales, $ 2,330 K
  • Annual Income, $ -83,810 K
  • EBIT $ -216 M
  • EBITDA $ -215 M
  • 60-Month Beta 2.57
  • Price/Sales 19.19
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -55.75
  • Most Recent Earnings $-3.43 on 11/09/23
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.67
  • Number of Estimates 1
  • High Estimate -0.67
  • Low Estimate -0.67
  • Prior Year -4.50
  • Growth Rate Est. (year over year) +85.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.43 +42.47%
on 11/10/23
Period Open: 10.66
12.54 -4.23%
on 10/30/23
+1.35 (+12.66%)
since 10/27/23
3-Month
8.43 +42.47%
on 11/10/23
Period Open: 13.07
16.58 -27.56%
on 09/08/23
-1.06 (-8.15%)
since 08/25/23
52-Week
2.66 +351.50%
on 06/21/23
Period Open: 31.00
32.75 -63.33%
on 11/28/22
-18.99 (-61.26%)
since 11/25/22

Most Recent Stories

More News
Aeglea: Q3 Earnings Snapshot

Aeglea: Q3 Earnings Snapshot

AGLE : 12.01 (+8.79%)
Aeglea BioTherapeutics Announces Grants of Inducement Awards

/PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the...

AGLE : 12.01 (+8.79%)
Aeglea BioTherapeutics to Participate in Upcoming September Conference

/PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the...

AGLE : 12.01 (+8.79%)
Aeglea BioTherapeutics Announces Reverse Stock Split

/PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the...

AGLE : 12.01 (+8.79%)
Aeglea BioTherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows and Heidy Abreu King-Jones

/PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the...

AGLE : 12.01 (+8.79%)
ARQT : 12.59 (-6.32%)
Aeglea: Q2 Earnings Snapshot

Aeglea: Q2 Earnings Snapshot

AGLE : 12.01 (+8.79%)
Aeglea BioTherapeutics Reports Second Quarter 2023 Financial Results

/PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea" or the "Company") (NASDAQ:AGLE), a biotechnology company advancing a pipeline of antibody therapeutics...

AGLE : 12.01 (+8.79%)
Aeglea BioTherapeutics Announces Sale of Pegzilarginase to Immedica Pharma

/PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ:AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with best-in-class...

AGLE : 12.01 (+8.79%)
Aeglea BioTherapeutics Announces Grant of Inducement Awards

/PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ: AGLE) today announced that, in connection with the acquisition of Spyre Therapeutics, Inc....

AGLE : 12.01 (+8.79%)
Increased Funding for Pancreatic Cancer Trials & Treatments Rising along with Demand for New Drugs

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:POAI),(NASDAQ:AGLE),(NASDAQ:TALS),(NASDAQ:MRTX) EQNX::TICKER_END

ONCY : 0.6229 (+24.56%)
ONC.TO : 0.88 (+25.71%)
AGLE : 12.01 (+8.79%)
TALS : 2.72 (-0.73%)
POAI : 0.9999 (+3.08%)
MRTX : 58.70 (-0.17%)

Business Summary

Aeglea BioTherapeutics, Inc. is a biotechnology company which is engaged in developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer. Its portfolio of products consists of AEB1102, AEB3103, AEB2109 and AEB4104 which are in different clinical...

See More

Key Turning Points

3rd Resistance Point 14.32
2nd Resistance Point 13.33
1st Resistance Point 12.67
Last Price 12.01
1st Support Level 11.02
2nd Support Level 10.03
3rd Support Level 9.37

See More

52-Week High 32.75
Fibonacci 61.8% 21.26
Fibonacci 50% 17.70
Fibonacci 38.2% 14.15
Last Price 12.01
52-Week Low 2.66

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar